Successful treatment of malaria depends on high-quality antimalarials, however, sub-standard, obsolete antimalarials, and oral artemisinin monotherapies remain readily available in many African countries through the private sector. These treatments may contain too little or no active ingredient, thereby putting patients’ lives at risk…“The Novartis Malaria Initiative is proud to host the 12th NMCP workshop as these meetings have led to groundbreaking projects that have significantly impacted the control of malaria,” said…[the] Head of the Novartis Malaria Initiative…Groundbreaking projects have emerged from past workshops, such as the SMS for Life program to support more efficient stock management in rural health facilities, and the development of…the first Artemisinin-based Combination Therapy (ACT) specifically tailored to infants and children, and meeting the World Health Organization requirements for a pediatric antimalarial medicine…